Researchers criticized Big Pharma for saying that prescription drug prices reflect R&D costs. A new study finds no correlation between research and development spending and outlandish drug prices. (Wired)
Novartis said it aims to cut its Irish workforce by up to 25%. The Swiss pharmaceutical giant said in June that the plan targeting savings of at least $1 billion by 2024 would reduce its total workforce of over 100,000 people by around 7.4%. (Reuters)
BridgeBio’s $2.4B partnership suffered an abrupt setback as Helsinn plans to withdraw the NDA on FGFR2 drug. LianBio, the biotech player that holds the China license to the drug, flagged the news in an SEC disclosure — although it appears that BridgeBio has previously reported it in a September filing. (Endpoints News)
The once-daunting monkeypox outbreak has begun to fade into the background. A few months ago, monkeypox regularly made headlines as a major public health crisis, then it largely vanished from the news. (The New York Times)
Doctors push back against NEJM study that casts doubt on the procedure. It turns out that more than half of the research participants who were ‘invited’ to get a colonoscopy never showed up for the procedure. (NPR)
